GUCY2F (Retinal Guanylate Cyclase 2F)

GUCY2F (Retinal Guanylate Cyclase 2F)

Overview

GUCY2F (guanylate cyclase 2F, also known as ROS-GC1 or GUCYA3) is a membrane-bound particulate guanylate cyclase specifically expressed in cone photoreceptor cells of the mammalian retina. It catalyzes the conversion of GTP to cGMP, the second messenger that maintains the cyclic nucleotide-gated (CNG) channels in the open state in the dark, thereby regulating the membrane potential and signal transduction of cone photoreceptors. GUCY2F is unique among membrane guanylate cyclases in its cone-specific expression pattern and its regulation by a distinct set of calcium-sensor proteins, the guanylate cyclase-activating proteins (GCAPs), which respond to the calcium changes that occur during the phototransduction cycle. Mutations in GUCY2F cause progressive cone dystrophy and are associated with achromatopsia in some cases. While primarily a retinal protein, GUCY2F provides insights into the broader biology of cyclic GMP signaling, calcium homeostasis, and photoreceptor survival mechanisms that are relevant to understanding neurodegeneration.

GUCY2F (Retinal Guanylate Cyclase 2F)

Overview

GUCY2F (guanylate cyclase 2F, also known as ROS-GC1 or GUCYA3) is a membrane-bound particulate guanylate cyclase specifically expressed in cone photoreceptor cells of the mammalian retina. It catalyzes the conversion of GTP to cGMP, the second messenger that maintains the cyclic nucleotide-gated (CNG) channels in the open state in the dark, thereby regulating the membrane potential and signal transduction of cone photoreceptors. GUCY2F is unique among membrane guanylate cyclases in its cone-specific expression pattern and its regulation by a distinct set of calcium-sensor proteins, the guanylate cyclase-activating proteins (GCAPs), which respond to the calcium changes that occur during the phototransduction cycle. Mutations in GUCY2F cause progressive cone dystrophy and are associated with achromatopsia in some cases. While primarily a retinal protein, GUCY2F provides insights into the broader biology of cyclic GMP signaling, calcium homeostasis, and photoreceptor survival mechanisms that are relevant to understanding neurodegeneration.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">GUCY2F Protein</th></tr>
<tr><td>Protein Name</td><td>Retinal guanylate cyclase 2F (ROS-GC1)</td></tr>
<tr><td>Gene</td><td>GUCY2F (GUCYA3)</td></tr>
<tr><td>UniProt ID</td><td>[P51841](https://www.uniprot.org/uniprot/P51841)</td></tr>
<tr><td>Molecular Weight</td><td>~120 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Cone outer segment disc membranes</td></tr>
<tr><td>Protein Family</td><td>Membrane-bound guanylate cyclase (particulate GC) family</td></tr>
<tr><td>Expression</td><td>Cone photoreceptors (retina-specific)</td></tr>
</table>
</div>

Structure

GUCY2F is a single-pass transmembrane protein of approximately 1,100 amino acids with the characteristic modular architecture of the membrane guanylate cyclase family:

Protein Domains

The catalytic domain contains the signature residues required for GTP binding and cyclization. Dimerization (via the catalytic domains) is required for activity — GUCY2F functions as a homodimer, with each monomer contributing to the catalytic pocket.

Normal Function

Role in Cone Phototransduction

GUCY2F is the primary source of cGMP production in the cone phototransduction cascade:

Regulation by GCAPs

GUCY2F is uniquely regulated by cone-specific guanylate cyclase-activating proteins:

• GCAP2 (GUCA2B): Primary activator of GUCY2F in cones. At high Ca2+ (dark), GCAP2 is calcium-bound and inactive. At low Ca2+ (light), GCAP2 releases Ca2+ and undergoes conformational change, activating GUCY2F.
• GCAP1 (GUCA2A): Contributes to GUCY2F regulation in some cone types.
• GCAP3 (GUCA2C): Expressed in a subset of cones, may provide additional regulation.

Comparison with Rod GC (GUCY1B)

GUCY2F is the cone ortholog of GUCY1B (ros gc), the rod guanylate cyclase:

| Feature | GUCY1B (Rod GC) | GUCY2F (Cone GC) |
|---------|-----------------|-------------------|
| Expression | Rod outer segments | Cone outer segments |
| Primary GCAP | GCAP1, GCAP2 | GCAP2 (predominant) |
| Activation kinetics | Slower recovery | Faster recovery |
| Ca2+ sensitivity | GCAP-dependent | GCAP-dependent |
| Pathologies | RP (if mutated) | Cone dystrophy, achromatopsia |

cGMP Signaling

cGMP produced by GUCY2F acts through two main effector pathways:

Clinical Significance

Cone Dystrophy

Mutations in GUCY2F cause progressive cone dystrophy [@dulgarianu2011]:

• Phenotype: Progressive loss of cone photoreceptor function, with relative preservation of rod function early in disease
• Symptoms: Decreased visual acuity, impaired color vision (particularly red-green discrimination), photophobia, and sensitivity to light
• Inheritance: Usually autosomal recessive
• Progression: Variable rate of cone degeneration; peripheral visual field typically preserved longer than central vision
• Electrophysiology: Severely reduced or absent cone ERG responses with relatively normal rod responses

Achromatopsia

Some GUCY2F mutations contribute to achromatopsia (rod monochromacy):

• Complete color blindness with reduced visual acuity, nystagmus, and photophobia from birth
• Typically autosomal recessive
• Often involves mutations in multiple cone phototransduction genes (GUCY2F, CNGA3, CNGB3, GNAT2, PDE6C, PDE6H)

Retinitis Pigmentosa

While GUCY1B is more commonly associated with RP, GUCY2F mutations can also cause retinal degeneration:

• Usually later onset and milder phenotype than rod-specific GC mutations
• Progressive cone-rod dystrophy pattern

Neurodegeneration Connections

Although GUCY2F is retina-specific, it offers insights into neurodegeneration mechanisms:

cGMP Signaling in the Brain

The cGMP signaling pathway parallels GUCY2F biology in neuronal contexts—but differs in important ways:

Soluble Guanylate Cyclase (sGC) vs. Particulate GC

| Feature | Soluble GC (sGC) | Particulate GC (GUCY2F) |
|---------|-------------------|--------------------------|
| Activation | Nitric oxide (NO) | GCAP proteins (Ca2+-dependent) |
| Location | Cytosol | Membrane-bound |
| Regulation | Heme-based NO sensing | Dimerization & GCAP binding |
| Brain expression | Neurons, glia | Limited (retina primarily) |

cGMP Dynamics in Neurodegeneration

Alzheimer's Disease:

• Reduced neuronal cGMP correlates with cognitive decline
• PDE5 upregulation reduces cGMP available for synaptic plasticity
• NO signaling—precursor to cGMP—is dysregulated in AD vasculature
• cGMP-raising agents (PDE5 inhibitors) improve memory in models

• D1 receptor coupling to cAMP/cGMP is disrupted
• nNOS activation in dopaminergic nuclei
• cGMP-gated channels in olfactory bulb—relevant to PD smell loss

• Ischemic preconditioning involves cGMP pathway activation
• NO donors are neuroprotective pre-conditioners
• sGC stimulators reduce infarct size in models

cGMP-Targeting Therapeutics

| Drug | Target | Mechanism | Neurodegeneration Application |
|------|-------|----------|----------------------|
| Sildenafil | PDE5 | Inhibits cGMP hydrolysis | Investigational for AD, stroke |
| Tadalafil | PDE5 | Longer half-life | Investigational for PD |
| Riociguat | sGC stimulator | NO-independent activation | Investigational for vascular cognitive impairment |
| Vericiguat | sGC stimulator | NO-independent activation | Cardiovascular, cognitive |

Calcium Feedback in Neurodegeneration

The GUCY2F-GCAP calcium feedback module is a model for understanding calcium dysregulation—a central feature of neurodegeneration:

Calcium Dysregulation in AD

• NMDA receptor overactivation: Leads to calpain activation
• ER calcium depletion: Aβ forms Ca2+-permeable pores
• Mitochondrial Ca2+ overload: Triggers mPTP opening
• Calpain-cdk5 activation: p25 generation drives tau pathology

Calcium Dysregulation in PD

• L-type Ca2+ channels: Cav1.3 vulnerability of dopaminergic neurons
• Mitochondrial Ca2+: Complex I deficiency affects Ca2+ handling
• ER stress: Ca2+ dysregulation triggers UPR
• Calpain activation: Contributes to α-synuclein aggregation

Calcium Sensor Parallels

GCAPs are neuronal calcium sensor (NCS) family members. Other NCS proteins:

• Recoverin: Photoreceptor-specific, involved in dark adaptation
• GCAP1/2/3: Retinal GCAPs activating guanylate cyclases
• Calmodulin: Ubiquitous Ca2+ sensor, regulates many enzymes
• NCS1 (NCS1): Neuronal calcium sensor 1

Photoreceptor Degeneration Models

The mechanisms of cone degeneration in GUCY2F mutations inform understanding of neuronal death:

Shared Mechanisms

Therapeutic Translation

Gene therapy approaches for GUCY2F-related cone dystrophy translate to neurodegeneration:

• AAV-mediated delivery: Standard CNS gene therapy vector
• Cone-specific promoters: Inform brain region-specific promoters
• CRISPR correction: Base editing for point mutations
• Optogenetic approaches: Light-sensitive channels bypass damage

Signaling Pathway Integration

Relationship to Other Retinal Proteins

GUCY2F integrates with multiple components of the phototransduction cascade:

Light → Rhodopsin (RHO) → GNAT2 (Transducin) → PDE6 → cGMP decrease
↓
CNG channels close
↓
Ca2+ decrease via Na+/Ca2+ exchanger
↓
GCAP activation → GUCY2F activation
↓
cGMP increase
↓
CNG channels open (recovery)

Downstream Effectors

CNG Channels (CNGA3/CNGB3)

• cGMP-gated, allows Na+ and Ca2+ influx
• Pore opening requires cGMP binding
• Conductance modulated by Ca2+/calmodulin

cGMP-Dependent Protein Kinase (PRKG)

• Less prominent in cones vs. rods
• May regulate adaptation mechanisms
• PRKG1 in many brain regions

Regulatory Network

GCAP Regulation

GCAPs sense Ca2+ via EF-hand domains:

• High Ca2+ (dark): Ca2+-GCAP binds GUCY2F but does not activate → channels close → hyperpolarization
• Low Ca2+ (light): Ca2+-free GCAP activates GUCY2F → cGMP synthesis → channels open → depolarization

Animal Models and Research Tools

Mouse Models

• Gucy2f knockout: Cone phototransduction defect, cone ERG loss
• Humanized GUCY2F knock-in: Modeling cone dystrophy mutations
• GCAP double knockout: Severe cone degeneration

Cell Models

• 661W cone cell line: Murine cone photoreceptor cells expressing GUCY2F
• ARPE-19 cells: Human retinal pigment epithelium, GCAP studies
• Stem cell-derived cones: Patient-specific modeling

Research Tools

• Recombinant GUCY2F: Protein for structural/functional studies
• GCAP fusion proteins: Ca2+ sensitivity assays
• cGMP analogs: 8-Br-cGMP, 8-pCPT-cGMP

Therapeutic Approaches

The cGMP signaling pathway parallels GUCY2F biology in neuronal contexts:

• Natriuretic peptide receptors (NPR-A, NPR-B): Membrane GCs in brain that respond to ANP/BNP peptides
• Soluble guanylate cyclases (sGC): NO-activated GCs in neurons — regulate synaptic plasticity, learning, and memory
• cGMP-dependent kinases (PRKG1, PRKG2): Neuronal signaling downstream of cGMP
• Phosphodiesterases (PDE5, PDE6, PDE9): cGMP degradation — PDE5 inhibitors (sildenafil, tadalafil) are neuroprotective in some contexts

Calcium Feedback in Neurodegeneration

The GUCY2F-GCAP calcium feedback module is a model for understanding calcium dysregulation:

• Calcium dysregulation in AD/PD: Impaired calcium homeostasis is a central feature of neurodegeneration
• GCAP-like proteins in brain: Some neuronal proteins share functional similarity with GCAPs in calcium sensing
• Calcium-dependent proteases: Calpains are activated by calcium influx and contribute to neurodegeneration — similar calcium sensitivity governs GUCY2F regulation

Photoreceptor Degeneration Models

The mechanisms of cone degeneration in GUCY2F mutations inform understanding of neuronal death:

• Loss of calcium homeostasis: Dysregulated Ca2+ leads to activation of calpains and caspases
• Protein aggregation: Misfolded GUCY2F may trigger ER stress and unfolded protein response
• Metabolic failure: cGMP depletion leads to CNG channel closure, disrupting ionic balance
• Oxidative stress: Cone photoreceptors have high metabolic demand and are vulnerable to oxidative damage

Therapeutic Approaches

Gene therapy approaches developed for GUCY2F-related cone dystrophy may translate to neurodegeneration:

• AAV-mediated gene replacement: Delivering functional GUCY2F to cone cells
• Genome editing: CRISPR-based correction of disease-causing mutations
• Optogenetic approaches: Bypassing damaged cones with light-sensitive channel expression

Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|----------------|----------------------|
| GCAP2 (GUCA2B) | Ca2+-dependent activation | Primary regulator of cyclase activity |
| GCAP1 (GUCA2A) | Activator | Contribute to GUCY2F regulation |
| GCAP3 (GUCA2C) | Activator | Species/retina-specific regulation |
| CNGA3 | Channel co-assembly | cGMP-gated ion influx |
| CNGB3 | Channel co-assembly | Channel localization and regulation |
| Transducin (GNAT2) | Downstream signaling | PDE6 activation reduces cGMP |
| PDE6 | Downstream signaling | Catalyzes cGMP hydrolysis |
| Recoverin | Modulator | Inactivates GNAT2 |
| S100B | Calcium binding | May modulate GCAP function |

Research Directions

See Also

• [Phototransduction Pathway](/mechanisms/phototransduction)
• [Cone Photoreceptor Cells](/cell-types/cone-photoreceptors)
• [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa)
• [Achromatopsia](/diseases/achromatopsia)
• [cGMP Signaling](/mechanisms/cgmp-signaling)
• [GCAP Proteins](/mechanisms/gcap-proteins)
• [Cone Dystrophy](/diseases/cone-dystrophy)
• [Rhodopsin](/proteins/rhodopsin)
• [GNAT2 Protein](/proteins/gnat2-protein)

References